The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Drug resistance in cancer: Principles of emergence and prevention
Open accessAbstract
Although targeted therapy is yielding promising results in the treatment of specific cancers, drug resistance poses a problem. We develop a mathematical framework that can be used to study the principles underlying the emergence and prevention of resistance in cancers treated with targeted small-molecule drugs. We consider a stochastic dynamical system based on measurable parameters, such as the turnover rate of tumor cells and the rate at which resistant mutants are generated. We find that resistance arises mainly before the start of treatment and, for cancers with high turnover rates, combination therapy is less likely to yield an advantage over single-drug therapy. We apply the mathematical framework to chronic myeloid leukemia. Early-stage chronic myeloid leukemia was the first case to be treated successfully with a targeted drug, imatinib (Novartis, Basel). This drug specifically inhibits the BCR-ABL oncogene, which is required for progression. Although drug resistance prevents successful treatment at later stages of the disease, our calculations suggest that, within the model assumptions, a combination of three targeted drugs with different specificities might overcome the problem of resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Self-renewal and solid tumor stem cells
Al-Hajj, M., & Clarke, M. F. (2004) · Oncogene · doi:10.1038/sj.onc.1207947 · Cited by 914
Virus dynamics and drug therapy
Bonhoeffer, S., May, R. M., Shaw, G. M., & Nowak, M. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6971 · Cited by 632
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Errors in DNA replication as a basis of malignant changes.
Loeb, L. A., Springgate, C. F., & Battula, N. (1974) · PubMed · Cited by 526
Chronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R., & Scapozza, L. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)00979-3 · Cited by 373
Imatinib as a Paradigm of Targeted Therapies
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91001-9 · Cited by 370
Strategies for reversing drug resistance
Fojo, T., & Bates, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206951 · Cited by 357
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
Nowicki, M. O., Falinski, R., Koptyra, M., Slupianek, A., Stoklosa, T., Gloc, E., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2004) · Blood · doi:10.1182/blood-2004-05-1941 · Cited by 278
Tlsty, T. D., Margolin, B. H., & Lum, K. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9441 · Cited by 246
Cancer Cells Exhibit a Mutator Phenotype
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60699-5 · Cited by 242
Antiangiogenic therapy and tumor progression
Blagosklonny, M. V. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00336-2 · Cited by 235
Production of resistant HIV mutants during antiretroviral therapy
Ribeiro, R. M., & Bonhoeffer, S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.7681 · Cited by 220
Simon, J. A., Szankasi, P., Nguyen, D. K., Ludlow, C. L., Dunstan, H. M., Roberts, C. J., Jensen, E. L., Hartwell, L. H., & Friend, S. H. (2000) · PubMed · Cited by 193
Mechanisms and implications of imatinib resistance mutations in BCR-ABL
Nardi, V., Azam, M., & Daley, G. Q. (2004) · Current Opinion in Hematology · doi:10.1097/00062752-200401000-00006 · Cited by 191
HIV-1 dynamics in vivo: implications for therapy
Simon, V., & Ho, D. D. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro772 · Cited by 170
Angiogenesis Inhibitors: A New Class of Drugs
Folkman, J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.212 · Cited by 164
Pre–existence and emergence of drug resistance in HIV–1 infection
Bonhoeffer, S., & Martin, A. (1997) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1997.0089 · Cited by 150
A stochastic model for the origin and treatment of tumors containing drug-resistant cells
Coldman, A. J., & Goldie, J. H. (1986) · Bulletin of Mathematical Biology · doi:10.1007/bf02459682 · Cited by 143
Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells
Tipping, A. J., Mahon, F., Lagarde, V., Goldman, J. M., & Melo, J. V. (2001) · Blood · doi:10.1182/blood.v98.13.3864 · Cited by 102
von Bubnoff, N. C. C., Veach, D. R., van der Kuip, H., Aulitzky, W. E., Sänger, J., Seipel, P., Bornmann, W. G., Peschel, C., CLARKSON, B., & Duyster, J. (2005) · Blood · doi:10.1182/blood-2004-06-2445 · Cited by 102
Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy
Smith, J. K., Mamoon, N. M., & Duhé, R. J. (2003) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000003772462298 · Cited by 96
Quantification of Cell Turnover Kinetics Using 5-Bromo-2′-deoxyuridine
Bonhoeffer, S., Mohri, H., Ho, D. D., & Perelson, A. S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5049 · Cited by 96
Introduction to resistance to anticancer agents
Kruh, G. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206932 · Cited by 94
McCormick, F. P. (2001) · Nature · doi:10.1038/35085665 · Cited by 75
Principles of Molecular Oncology
Hermeking, H. (2000) · Humana Press · doi:10.1007/978-1-59259-664-5 · Cited by 72
Recent Advancements in the Treatment of Chronic Myelogenous Leukemia
O'Dwyer, M. E., Mauro, M. J., & Druker, B. J. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103853 · Cited by 72
Resistance in the land of molecular cancer therapeutics
Shannon, K. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00101-0 · Cited by 67
Yoshida, C., & Melo, J. V. (2004) · International Journal of Hematology · doi:10.1532/ijh97.04032 · Cited by 47
Blagosklonny, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402409 · Cited by 37
Cited by
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Electrospinning for drug delivery applications: A review
Luraghi, A., Peri, F., & Moroni, L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.033 · Cited by 746
The mathematics of cancer: integrating quantitative models
Altrock, P. M., Liu, L. L., & Michor, F. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4029 · Cited by 685
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
Gillies, R. J., Verduzco, D., & Gatenby, R. A. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3298 · Cited by 684
Metadata
- Authors
- Komarova, N. L., & Wodarz, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-06-24
- Volume
- 102
- Issue
- 27
- Pages
- 9714-9719
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2094556422
- Cited by
- 414
- References
- 35
- FWCI
- 31.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.